Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.
Rathkopf, D. E., Smith, M. R., De Bono, J. S., Logothetis, C., Shore, N. D., De Souza, P. L., . . . Ryan, C. J. (2013). Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.. Journal of Clinical Oncology, 31(6_suppl), 5. doi:10.1200/jco.2013.31.6_suppl.5
Rathkopf, D. E., Smith, M. R., De Bono, J. S., Logothetis, C., Shore, N. D., De Souza, P. L., . . . Ryan, C. J. (2013). Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.. Journal of Clinical Oncology, 31(6_suppl), 5. doi:10.1200/jco.2013.31.6_suppl.5